Related references
Note: Only part of the references are listed.Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
Miguel Martin et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Reduction of CD44+/CD24- breast cancer cells by conventional cytotoxic chemotherapy
Sebastian Aulmann et al.
HUMAN PATHOLOGY (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Anthracyclines and Early Breast Cancer: The End of an Era?
Luca Gianni
JOURNAL OF CLINICAL ONCOLOGY (2009)
Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Topoisomerase IIα Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out
Francisco J. Esteva et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status
Raymond Tubbs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?
Kathleen I. Pritchard
JOURNAL OF CLINICAL ONCOLOGY (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
Stephen Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor-Positive Breast Cancer
Frederique Penault-Llorca et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers
Dennis J. Slamon et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
F. P. O'Malley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis et al.
LANCET (2009)
Class III β-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel
Carlos M. Galmarini et al.
CLINICAL CANCER RESEARCH (2008)
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis
Chad J. Creighton et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel:: Breast International Group 02-98 randomized trial
Prudence Francis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Miguel Martin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers
Yasuo Miyoshi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
Christine M. Fillmore et al.
BREAST CANCER RESEARCH (2008)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancer
Edurne Arriola et al.
EUROPEAN JOURNAL OF CANCER (2006)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Predictive factors for response to docetaxel in human breast cancers
Shinzaburo Noguchi
CANCER SCIENCE (2006)
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers
YL Tham et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
WJ Gradishar et al.
ANNALS OF ONCOLOGY (2005)
Adjuvant docetaxel for node-positive breast cancer
M Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
EP Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma
PA Learn et al.
CANCER (2005)
Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
RE Mueller et al.
GENES CHROMOSOMES & CANCER (2004)
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
A Di Leo et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma
AM Gonzalez-Angulo et al.
CANCER (2004)
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
T Petit et al.
EUROPEAN JOURNAL OF CANCER (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
F Zhang et al.
CANCER (2003)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
K Park et al.
EUROPEAN JOURNAL OF CANCER (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
A Di Leo et al.
ANNALS OF ONCOLOGY (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
